Bulk Inquiry
GLP-1R agonist DMB
- DMB
Axon 1907
CAS:
281209-71-0
Purity:
99%
- Soluble in DMSO
- MF: C13H15Cl2N3O2S
- MW: 348.25
Description
GLP-1R agonist DMB is a glucagon-like peptide-1 receptor (GLP-1R) agonist used to activate incretin receptor signaling.
GLP-1R signaling promotes cAMP production, insulin secretion and metabolic regulation, making GLP-1 receptor agonists important tools for diabetes and obesity research. GLP-1R agonist DMB supports in vitro and in vivo investigation of incretin biology.
Key Features
- GLP-1 receptor agonist
- Activates incretin GPCR signaling
- Relevant to insulin secretion and glucose homeostasis
- Useful for diabetes and obesity model research
Applications
- GLP-1R functional assays
- cAMP and incretin signaling studies
- β-cell insulin secretion research
- Metabolic disease and obesity pharmacology models
More Information
| Parent CAS No. | 281209-71-0 |
|---|---|
| Chemical Name | N-tert-butyl-6,7-dichloro-3-(methylsulfonyl)quinoxalin-2-amine |
| SMILES | N1C2C(=CC(Cl)=C(Cl)C=2)N=C(S(C)(=O)=O)C=1NC(C)(C)C |
| MFCD | MFCD11521508 |
| InChi | InChI=1S/C13H15Cl2N3O2S/c1-13(2,3)18-11-12(21(4,19)20)17-10-6-8(15)7(14)5-9(10)16-11/h5-6H,1-4H3,(H,16,18) |
| InChiKey | GNZCSGYHILBXLL-UHFFFAOYSA-N |
| CID | 16007289 |
| Short Description | GLP1R agonist |
GLP-1R agonist DMB
GLP-1 receptor agonist
DMB
GLP-1RagonistDMB
GLP-1
GLP-1 receptor
Agonist
cAMP signaling
GPCR signaling
GLP-1R functional assays
cAMP and incretin signaling studies
β-cell insulin secretion research
Metabolic disease and obesity pharmacology models
metabolism
diabetes research
obesity research
GPCR pharmacology
signal transduction
GPCR
CAS 281209-71-0
Axon Medchem
Axon 1907
Supplier
Vendor
References
- LB Knudsen et al. Small molecule agonists for the glucagon-like peptide-1 receptor. Proc. Natl. Acad. Sci. USA, 2007, 104(3), 937-942. (*compound 2 in this article)
- C Koole et al. Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner; implications for drug screening. Mol. Pharmacol. 2010, 78(3), 456-465.
- N Irwin et al. Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline. Eur. J. Pharmacol. 2010, 1-3, 268-273.
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1132 | GLP-1 antagonist |
From $165.00 |
| 2259 | BETP |
From $115.50 |
| 2388 | Adomeglivant |
From $104.50 |
Other Categories
Get a Quote for
Loading...